SLE is a heterogeneous disease, which can cause many different manifestations and symptoms, and traditionally did not have many treatment options. However, the picture is changing, and clinical ...

When people with systemic lupus erythematosus (SLE) actively participate in shared decision-making (SDM) about their disease with their doctors’, trust is likely to increase. A new study found that ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem involvement. Systemic sclerosis (SSc) or scleroderma is another rheumatic autoimmune disease that ...

SLE is a heterogeneous disease, which can cause many different manifestations and symptoms, and traditionally did not have many treatment options. However, the picture is changing, and clinical ...

New data identify age, anti-β2GP1 antibodies, and low C3 as key risk factors for cerebral small vessel disease in systemic ...

The SLECRISK tool for predicting cardiovascular disease among patients with systemic lupus erythematosus produces more accurate predictions compared with the American College of Cardiology/American ...

Please provide your email address to receive an email when new articles are posted on . The acceptable threshold for glucocorticoid use for lupus maintenance therapy should be 5 mg per day prednisone ...

The market opportunities for SLE and LN lie in developing targeted therapies, guided by an understanding of epidemiological trends across major markets. Focus on age, sex, and severity can enhance ...

The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...

Women with lupus face unique challenges regarding family planning and pregnancy. In a recent study, researchers looked at the impact of pregnancy planning and medical readiness on reproductive ...